Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors for treatment of high cholesterol levels effectiveness and value

JAMA Internal Medicine

Volumn 176, Issue 1, 2016, Pages 107-108

  Tice, Jeffrey A ^a   Kazi, Dhruv S ^a,b   Pearson, Steven D ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c INSTITUTE FOR CLINICAL AND ECONOMIC REVIEW   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALIROCUMAB; CHOLESTEROL; EVOLOCUMAB; EZETIMIBE; FIBRIC ACID DERIVATIVE; KEXIN; LIVER ENZYME; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID; PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9 INHIBITOR; SERINE PROTEINASE INHIBITOR; SUBTILISIN; UNCLASSIFIED DRUG; HYPOCHOLESTEROLEMIC AGENT; MONOCLONAL ANTIBODY; PCSK9 PROTEIN, HUMAN; SERINE PROTEINASE;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CHOLESTEROL BLOOD LEVEL; CLINICAL EFFECTIVENESS; COGNITION; COMPARATIVE EFFECTIVENESS; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG UPTAKE; ESTROGEN THERAPY; FAMILIAL HYPERCHOLESTEROLEMIA; GROSS NATIONAL PRODUCT; HEART INFARCTION; HIGH RISK POPULATION; HUMAN; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; ANTAGONISTS AND INHIBITORS; BLOOD; CARDIOVASCULAR DISEASES; COST BENEFIT ANALYSIS; ECONOMICS; HYPERCHOLESTEROLEMIA; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL; ANTICHOLESTEREMIC AGENTS; CARDIOVASCULAR DISEASES; CHOLESTEROL, LDL; COST-BENEFIT ANALYSIS; HUMANS; HYPERCHOLESTEROLEMIA; PROPROTEIN CONVERTASES; SERINE ENDOPEPTIDASES; TREATMENT OUTCOME;

EID: 84954521357     PISSN: 21686106     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamainternmed.2015.7248     Document Type: Review

References (8)

1. Tice JA, Kazi DS, Ollendorf DA, et al. PCSK9 inhibitors for treatment of high cholesterol. 2015. http://cepac.icer-review.org/wp-content/uploads/2015/04/PCSK9-REVISED-Draft-Report-100815.pdf. Accessed October 8, 2015.
2. Mozaffarian D, Benjamin EJ, Go AS, et al; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics-2015 update. Circulation. 2015;131(4):e29-e322.
3. Navarese EP, Kolodziejczak M, Schulze V, et al. Effects of proprotein convertase subtilisin/kexin type 9 antibodies in adults with hypercholesterolemia. Ann Intern Med. 2015;163(1): 40-51.
4. Moran AE, Odden MC, Thanataveerat A, et al. Cost-effectiveness of hypertension therapy according to 2014 guidelines. N Engl J Med. 2015; 372(5):447-455.
5. Institute for Clinical and Economic Review. Value assessment project: a framework to guide payer assessment of the value of medical services. 2014. http://www.icer-review.org/wp-content/uploads/2014/01/Slides-on-value-framework-for-national-webinar1.pdf. Accessed 10/8/2015.
6. Langslet G, Emery M, Wasserman SM. Evolocumab (AMG 145) for primary hypercholesterolemia. Expert Rev Cardiovasc Ther. 2015;13(5):477-488.
7. Schwartz GG, Bessac L, Berdan LG, et al. Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes. Am Heart J. 2014;168(5): 682-689.
8. Anderson JL, Heidenreich PA, Barnett PG, et al. ACC/AHA statement on cost/value methodology in clinical practice guidelines and performance measures. J Am Coll Cardiol. 2014;63(21):2304-2322.